6463-41-8

Basic information

• Product Name: 1H-Pyrazol-3-amine, 1-(3-chlorophenyl)-4,5-dihydro-
• CAS NO: 6463-41-8
• Molecular Formula: C9H10ClN3
• Molecular Weight: 195.651
• Mol File: 6463-41-8.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 1H-Pyrazol-3-amine, 1-(3-chlorophenyl)-4,5-dihydro-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrazol-3-amine, 1-(3-chlorophenyl)-4,5-dihydro-(6463-41-8)
• EPA Substance Registry System: 1H-Pyrazol-3-amine, 1-(3-chlorophenyl)-4,5-dihydro-(6463-41-8)

Safety Data

• Hazardous Substances Data: 6463-41-8(Hazardous Substances Data)

Usage

Chemical group

Pyrazole derivatives

Appearance

White to light yellow solid

Use in pharmaceutical industry

Building block and intermediate for the synthesis of various pharmaceutical drugs and active ingredients

Potential applications

Development of new drugs for the treatment of various medical conditions

Safety

Handle with care and follow safety protocols due to potential hazardous properties

Importance

Valuable chemical compound with important industrial and pharmaceutical applications

Upstream product

• 107-13-1 acrylonitrile 
• 14763-20-3 3-chlorophenyl hydrazine 
• 2312-23-4 m-chlorophenylhydrazine hydrochloride 

Downstream Products

• 65740-38-7 1-(3-chlorophenyl)-3-aminopyrazole 
• 104164-07-0 5-chloromethyl-1-(3-chlorophenyl)-1H,7H-pyrazolo<1,5-a>pyrimidine-7-one 

Relevant articles and documents

3-AMINOPYRAZOLINES FOR TREATMENT OF NEURODEGENERATIVE AND PSYCHIATRIC DISEASES

Compounds of the formula (I), inhibit D-amino acid oxidase and hence find use in treating degenerative and psychiatric diseases.

Pharmaceutical formulations

Heterocyclic compounds of formula (I) STR1 and their acid addition salts, when administered topically, exhibit anti-inflammatory activity and do not produce the side-effects associated with the administration of certain other anti-inflammatories. The compounds of formula (I) may be administered topically as the compound alone or in a suitable topical pharmaceutical formulation.

3-Trifluoroacetylamino-1-aryl-2-pyrazolines

This disclosure describes novel 3-substituted amino-1-phenyl-2-pyrazolines and 3-substituted amino-1-mono and disubstituted phenyl-2-pyrazolines and their C4 and C5 analogs, useful for meliorating the inflammation and/or the progressive joint deterioration characteristic of arthritic disease, preventing the onset of asthmatic symptoms and allergic diseases, or as analgesic, antibacterial or antifungal agents.